Sai Parenterals Limited (NSE: SAIPARENT) has announced its un-audited financial results for the quarter and half-year ended 30th September 2026, showcasing significant growth and strategic advancements. Revenue from operations stood at Rs. 196.1 crore, up 9.0% quarter-over-quarter (QoQ) from Rs. 179.9 crore in Q1FY27. The first half of FY27 revenue of Rs. 376.0 crore represents approximately 50% of the FY27 revenue target of Rs. 750 crore, ahead of the guided 45:55 phasing between the two halves.

Key Financial Highlights

Gross profit stood at Rs. 93.1 crore, up 26.4% QoQ, with gross margin rising to 47.5% from 40.9% in Q1FY27. The improvement reflects tighter inventory management: higher-cost inventory from earlier periods was consumed, and first-in, first-out controls were introduced on a new ERP system. EBITDA stood at Rs. 41.4 crore, up 67.4% QoQ, with EBITDA margin at 21.1% against 13.7% in Q1FY27. Despite a more than threefold sequential rise in depreciation, PAT grew 32.7% QoQ to Rs. 10.5 crore in Q2FY27.

Strategic Developments

Following shareholders’ approval of the variation in the objects of the issue, the Company has completed the acquisition of 60% stakes in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited. It invested Rs. 98.8 crore of IPO proceeds: Rs. 83.83 crore in Saicriti and Rs. 15 crore in Prathyak. The purpose for which the IPO funds were raised remains unchanged: EU-GMP compliant injectable capacity for regulated markets, and a dedicated research and development platform.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 12.4% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock holds at 28% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 126.1% and profits at 111.8% CAGR, with D/E of 0.00. Meanwhile, the stock dips 12.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.

CORONA Remedies Limited (CORONA) has announced its unaudited financial results for the quarter and half year ended September 30, 2026, delivering the highest ever revenue with a growth of 22% year-on-year (Y-o-Y) basis. This impressive performance marks a significant milestone for the company, which continues to be one of the fastest growing companies among the top 30 Indian pharmaceutical companies.

Financial Performance

The financial performance snapshot reveals robust growth across key metrics. Revenue from operations stood at ₹441.2 crore for Q2FY27, a 22.2% increase compared to ₹361.1 crore in Q2FY26. EBITDA rose to ₹96.0 crore, up 22.3% from ₹78.5 crore in the same quarter last year. Profit After Tax (PAT) increased to ₹60.3 crore, reflecting a 15.3% growth from ₹52.3 crore in Q2FY26.

Key Business Highlights

CORONA Remedies Limited has demonstrated operational excellence and disciplined execution, leveraging all growth drivers to outperform the Indian Pharmaceutical Market (IPM). The company has now outpaced the IPM growth by 1.9 times as per MAT Sep’26. Additionally, CORONA has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad.

Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “We are pleased to announce another quarter of strong, consistent growth. This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence, and investing in capabilities that will support our future growth.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

Sanofi India Limited’s board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on October 29, 2026. The meeting focused on strategic initiatives and operational updates, underscoring the company’s commitment to innovation and growth in the pharmaceutical sector.

Strategic Initiatives

The board deliberated on several strategic initiatives aimed at expanding market reach and enhancing product portfolios. Notably, the meeting highlighted plans to strengthen partnerships in the cardiovascular and diabetes segments, which are pivotal to the company’s growth strategy.

Operational Updates

The meeting also provided updates on operational efficiencies and cost management. The board reviewed measures taken to improve gross margins and operational efficiencies, which have contributed to the company’s robust financial performance.

Future Outlook

As a result of these strategic discussions and operational reviews, Sanofi India Limited is poised to continue its momentum in the pharmaceutical industry, focusing on sustainable long-term value creation and market leadership.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sanofi India Limited

Sanofi India Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sanofi falls 13.8% over three months and has not found a floor yet. D/E of 0.00 and a 4.16% dividend yield give the balance sheet a decent cushion. The 4.16% dividend yield is about the only thing keeping income investors interested right now. The stock sits at 2% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at -12.6% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Sanofi India Limited.